Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain
Authors
Keywords
-
Journal
AIDS
Volume 36, Issue 10, Pages 1337-1344
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-06-21
DOI
10.1097/qad.0000000000003245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV‐1‐infected patients: a real‐world study in Japan
- (2021) Naoki Kanda et al. HIV MEDICINE
- Weight gain before and after switch from TDF to TAF in a U.S. cohort study
- (2021) Patrick WG Mallon et al. Journal of the International AIDS Society
- Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients
- (2021) Maria Saumoy et al. Journal of Clinical Medicine
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- (2020) Jan Borén et al. EUROPEAN HEART JOURNAL
- The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
- (2020) Nicola Squillace et al. Drug Design Development and Therapy
- Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era
- (2020) Stephanie A. Ruderman et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate
- (2019) Samir K. Gupta et al. AIDS
- Lipid changes due to tenofovir alafenamide are reversible by switching back to tenofovir disoproxil fumarate
- (2019) Ana Milinkovic et al. AIDS
- Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting
- (2019) Kai Juhani Kauppinen et al. AIDS PATIENT CARE AND STDS
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Changes in Body Mass Index and Atherosclerotic Disease Risk Score after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
- (2019) Jason J Schafer et al. Open Forum Infectious Diseases
- A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
- (2018) Joseph J. Eron et al. AIDS
- Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine
- (2018) David V Glidden et al. CLINICAL INFECTIOUS DISEASES
- A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
- (2018) Mario Gomez et al. INFECTION
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada
- (2016) John R. Koethe et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
- (2016) Adrian S. Ray et al. ANTIVIRAL RESEARCH
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
- (2015) José R. Santos et al. CLINICAL INFECTIOUS DISEASES
- Intra-individual changes in body weight in population-based cohorts during four decades: the Finnish FINRISK study
- (2010) Pia Pajunen et al. EUROPEAN JOURNAL OF PUBLIC HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More